Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. DSM-Firmenich AG's accounts receivables for the quarter that ended in Jun. 2026 was CHF2,011 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
DSM-Firmenich AG's Days Sales Outstanding for the quarter that ended in Jun. 2026 was 85.46.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. DSM-Firmenich AG's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was CHF-28.20.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
DSM-Firmenich AG's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), DSM-Firmenich AG's accounts receivable are only considered to be worth 75% of book value:
DSM-Firmenich AG's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
DSM-Firmenich AG Accounts Receivable Related Terms
DSM-Firmenich AG Accounts Receivable Historical Data
* Premium members only.
The historical data trend for DSM-Firmenich AG's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Accounts Receivable of CHF2,011 Mil mean?
DSM-Firmenich AG (XSWX:DSFIR) has a Accounts Receivable of CHF2,011 Mil as of Jun. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on DSM-Firmenich AG and its competitors.
Is DSM-Firmenich AG's Accounts Receivable too high?
DSM-Firmenich AG's current Accounts Receivable is CHF2,011 Mil. Overall, DSM-Firmenich AG has a GF Score™ of 31/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does DSM-Firmenich AG's Accounts Receivable compare to LIN and SHW?
DSM-Firmenich AG's Accounts Receivable of CHF2,011 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Chemicals company?
A good Accounts Receivable depends on the Chemicals industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on DSM-Firmenich AG and its competitors. DSM-Firmenich AG's current Accounts Receivable is CHF2,011 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DSM-Firmenich AG stock overvalued right now?
Based on GuruFocus' analysis, DSM-Firmenich AG (XSWX:DSFIR) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF78.44, compared to a current price of CHF87.90 — trading 12.1% above its estimated fair value. The current Accounts Receivable is CHF2,011 Mil. DSM-Firmenich AG's overall GF Score™ is 31/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For DSM-Firmenich AG (XSWX:DSFIR), the current Accounts Receivable is CHF2,011 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DSM-Firmenich AG (XSWX:DSFIR) Overvalued in 2026?
Based on GuruFocus' analysis, DSM-Firmenich AG stock appears to be overvalued.
The current stock price of CHF87.90 is trading 12.1% above its estimated GF Value™ of CHF78.44.
GuruFocus considers DSM-Firmenich AG to be Modestly Overvalued.
Key valuation signals for XSWX:DSFIR:
Accounts Receivable: CHF2,011 Mil
GF Value™: CHF78.44 vs. price of CHF87.90 (12.1% above fair value)
No single metric tells the full story. See the XSWX:DSFIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DSM-Firmenich is a global science-based company formed in 2023 through the merger of DSM, a Dutch nutrition, health, and sustainable living player, and Switzerland-based Firmenich, the third-largest player in the flavor and fragrance market. The company serves a wide range of end-consumer markets providing nutrition solutions ranging from medical and early-life nutrition, fragrances for personal-, home-, and laundry-care brands, prestige perfumes, and other ingredients for food and beverage, home, and personal care. DSM-Firmenich has nearly 30,000 employees, with more than 2,000 scientists and engineers spread across 15 research and development facilities.
31GF Score
Get the complete analysis for XSWX:DSFIR
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:DSFIR has been successfully added to your 
